Iqvia (NYSE:IQV) had its target price increased by JPMorgan Chase & Co. from $180.00 to $195.00 in a research report report published on Thursday morning, The Fly reports. The brokerage currently has an overweight rating on the medical research company’s stock.
IQV has been the subject of several other research reports. ValuEngine downgraded shares of Iqvia from a hold rating to a sell rating in a research report on Tuesday, February 4th. Citigroup increased their price objective on shares of Iqvia from $185.00 to $195.00 and gave the stock a buy rating in a research report on Thursday. Credit Suisse Group reissued a buy rating and set a $170.00 price objective on shares of Iqvia in a research report on Friday, December 20th. Cfra raised shares of Iqvia from a hold rating to a buy rating and increased their price objective for the stock from $148.00 to $185.00 in a research report on Wednesday. Finally, Zacks Investment Research raised shares of Iqvia from a sell rating to a hold rating and set a $170.00 price objective for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $174.30.
NYSE:IQV traded down $1.47 during trading hours on Thursday, hitting $164.32. The stock had a trading volume of 2,962,308 shares, compared to its average volume of 1,312,776. Iqvia has a one year low of $130.77 and a one year high of $169.14. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.12 and a current ratio of 1.12. The company has a market cap of $31.03 billion, a price-to-earnings ratio of 134.69, a P/E/G ratio of 1.70 and a beta of 0.91. The business’s 50 day moving average is $158.20 and its 200-day moving average is $151.72.
In related news, CFO Michael R. Mcdonnell sold 12,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total value of $1,860,840.00. Following the completion of the transaction, the chief financial officer now owns 14,366 shares of the company’s stock, valued at $2,227,735.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Evanisko sold 6,250 shares of the firm’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $160.76, for a total transaction of $1,004,750.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,000 shares of company stock valued at $5,830,215. 6.00% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in IQV. Usca Ria LLC bought a new position in Iqvia in the third quarter valued at $29,000. Penserra Capital Management LLC grew its position in Iqvia by 57.5% in the fourth quarter. Penserra Capital Management LLC now owns 189 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 69 shares in the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Iqvia by 379.5% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 211 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 167 shares in the last quarter. Evolution Wealth Advisors LLC grew its position in Iqvia by 303.6% in the fourth quarter. Evolution Wealth Advisors LLC now owns 222 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 167 shares in the last quarter. Finally, Citizens Financial Group Inc RI bought a new position in Iqvia in the fourth quarter valued at $34,000. 89.93% of the stock is owned by institutional investors and hedge funds.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also: What is quantitative easing?
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.